The additional value of myocardial T1ρ mapping to T1 and T2 mapping for predicting subsequent cancer therapy-related cardiac dysfunction in breast cancer patients who received anthracyclines with/without trastuzumab.

OBJECTIVES

We aimed to describe changes in parameters derived from myocardial T1ρ, T1, and T2 mapping and assess whether incorporating T1ρ mapping improves the predictive performance of T1 and T2 mapping for subsequent cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients treated with anthracyclines with/without trastuzumab.

METHODS

From March 2021 to May 2023, 82 participants with breast cancer treated with anthracyclines with/without trastuzumab were prospectively recruited. Cardiac magnetic resonance was performed at baseline, 3 and 6 months in relation to baseline. T1ρ, T1 and T2 values were measured and compared by repeated measures analyses of variance. Logistic regression and receiver operating characteristic analysis were used to assess the performance in predicting subsequent CTRCD.

RESULTS

Nineteen (23.17 %) participants developed CTRCD. T1ρ and T1 values progressively increased over time (all p < 0.001), while T2 values increased at 3 (p < 0.001 and p = 0.002, respectively) and 6 months (all p < 0.001) compared to baseline in both the CTRCD (+) and CTRCD (-) groups. The changes in T1ρ (OR, 3.892, p = 0.003) and T1 (OR, 1.082, p = 0.002) from baseline to 3 months were associated with subsequent CTRCD. The combination of the changes in T1ρ and T1 from baseline to 3 months obtained an improved area under the curve of 0.853.

CONCLUSION

T1ρ, T1 and T2 increased after treatment of anthracyclines with/without trastuzumab. Myocardial T1ρ mapping provides additional predictive value to T1 mapping for subsequent CTRCD in breast cancer patients who received anthracyclines with/without trastuzumab.

CLINICAL RELEVANCE STATEMENT

Myocardial T1ρ mapping offers additional predictive value to T1 and T2 mapping for subsequent CTRCD in breast cancer patients who received anthracyclines with/without trastuzumab. This may facilitate accurate prediction of cardiotoxicity and personalized treatment decision making in breast cancer.